Literature DB >> 9302196

Production of reassortant viruses containing human rotavirus VP4 and SA11 VP7 for measuring neutralizing antibody following natural infection.

R J Gorrell1, R F Bishop.   

Abstract

The outer capsid proteins VP4 and VP7 of group A rotaviruses are both targets of neutralizing antibody produced following natural infection in humans. Of interest is the relative importance and immunodominance of each protein in the generation of a protective immune response. In order to measure neutralizing antibody responses to VP4 and VP7 separately, reassortants bearing VP4 of each of the major human rotavirus P types with VP7 of SA11 origin were successfully produced by neutralizing monoclonal antibody selection. The resulting reassortants, together with reassortants representing each of the major VP7 types, were antigenically characterized with serotype-specific neutralizing monoclonal antibodies and hyperimmune sera. The neutralization proteins of human rotavirus origin were found to be unaffected antigenically by reassortment. The abilities of these reassortants to discriminate between VP4 and VP7 immune responses were evaluated with postinfection sera collected from three patients infected with either a P1A[8],G1, a P1B[4],G2, or a P1A[8],G4 rotavirus strain. The reassortants were shown to be capable of separating the neutralizing antibody responses to VP4 and VP7, with each patient showing a different immune response with respect to VP4 or VP7 immunodominance. These reassortants can now be applied to analyses of individual immune responses to VP4 and VP7 proteins after primary rotavirus infections and reinfections in humans.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9302196      PMCID: PMC170582          DOI: 10.1128/cdli.4.5.509-514.1997

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  27 in total

1.  Localization of rotavirus VP4 neutralization epitopes involved in antibody-induced conformational changes of virus structure.

Authors:  Y J Zhou; J W Burns; Y Morita; T Tanaka; M K Estes
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

2.  Efficient production of antigenic mosaic reassortants of rotavirus with the aid of anti-VP4 and anti-VP7 neutralizing monoclonal antibodies.

Authors:  N Kobayashi; K Taniguchi; T Urasawa; S Urasawa
Journal:  J Virol Methods       Date:  1993-09       Impact factor: 2.014

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Amino acids involved in distinguishing between monotypes of rotavirus G serotypes 2 and 4.

Authors:  B S Coulson; C D Kirkwood; P J Masendycz; R F Bishop; G Gerna
Journal:  J Gen Virol       Date:  1996-02       Impact factor: 3.891

5.  Evaluation of a bovine-human rotavirus reassortant vaccine in infants.

Authors:  C Christy; P Offit; H F Clark; J Treanar
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

6.  Differences in plaque size and VP4 sequence found in SA11 virus clones having simian authentic VP4.

Authors:  K Taniguchi; K Nishikawa; N Kobayashi; T Urasawa; H Wu; M Gorziglia; S Urasawa
Journal:  Virology       Date:  1994-01       Impact factor: 3.616

7.  Studies on the role of VP4 of G serotype 10 rotavirus (B223) in the induction of the heterologous immune response in calves.

Authors:  Z Xu; G N Woode
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

8.  Immunodominant neutralizing antigens depend on the virus strain during a primary immune response in calves to bovine rotaviruses.

Authors:  Z Xu; M E Hardy; J D Williams; G N Woode; R F Ramig
Journal:  Vet Microbiol       Date:  1993-05       Impact factor: 3.293

9.  Genotypic diversity of reassortants between simian rotavirus SA11 and human rotaviruses having different antigenic specificities and RNA patterns.

Authors:  N Kobayashi; K Kojima; K Taniguchi; T Urasawa; S Urasawa
Journal:  Res Virol       Date:  1994 Sep-Oct

10.  Rotavirus antigenicity is affected by the genetic context and glycosylation of VP7.

Authors:  I Lazdins; B S Coulson; C Kirkwood; M Dyall-Smith; P J Masendycz; S Sonza; I H Holmes
Journal:  Virology       Date:  1995-05-10       Impact factor: 3.616

View more
  4 in total

1.  Serotype specificity of the neutralizing-antibody response induced by the individual surface proteins of rotavirus in natural infections of young children.

Authors:  G Menchaca; L Padilla-Noriega; M Méndez-Toss; J F Contreras; F I Puerto; H Guiscafré; F Mota; I Herrera; R Cedillo; O Muñoz; R Ward; Y Hoshino; S López; C F Arias
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

2.  Prevalence of neutralizing antibodies against different rotavirus serotypes in children with severe rotavirus-induced diarrhea and their mothers.

Authors:  Pratibha G Ray; Shobhana D Kelkar
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

3.  Generation of Simian Rotavirus Reassortants with VP4- and VP7-Encoding Genome Segments from Human Strains Circulating in Africa Using Reverse Genetics.

Authors:  Alexander Falkenhagen; Corinna Patzina-Mehling; Ashish K Gadicherla; Amy Strydom; Hester G O'Neill; Reimar Johne
Journal:  Viruses       Date:  2020-02-11       Impact factor: 5.048

4.  Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity.

Authors:  M Ciarlet; S E Crawford; C Barone; A Bertolotti-Ciarlet; R F Ramig; M K Estes; M E Conner
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.